New LaunchApr 13, 2026, 06:51 AM
ANI Pharma Launches Generic Carbamazepine ER Capsules; $65M Market
AI Summary
ANI Pharmaceuticals, Inc. announced the launch of Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg strengths. This product is the generic version of Carbatrol® and is considered a limited competition product, aiming to improve patient access to essential medicines. The U.S. annual sales for Carbamazepine Extended-Release Capsules are approximately $65 million, based on February 2026 IQVIA data.
Key Highlights
- ANI Pharmaceuticals launched Carbamazepine Extended-Release Capsules.
- It is a generic version of Carbatrol®.
- U.S. annual sales for the product total approximately $65 million.
- The product is considered a limited competition generic.
Price Impact
More from ANIP